Haldor Topsøe remains the largest shareholder of cancer treatment developer IGM Biosciences, whose shares have risen more than 50% since it floated yesterday.
US-based cancer therapy developer IGM Biosciences went public yesterday in a $175m initial public offering that scored an exit for catalyst producer Haldor Topsøe.
The company priced more than 10.9 million shares on the Nasdaq Global Select Market at $16.00 each, in the middle of the IPO’s $15 to $17 range, giving it a market capitalisation of approximately $463m.
IGM was formerly known as Palingen before rebranding in 2010 to focus on a platform that produces engineered immunoglobulin M…
